Therefore, this study investigated whether it is possible to detect RASSF1A epigenetic alterations in the serum of neuroblastoma patients, and aberrant RASSF1A methylation in patient pretherapeutic serum is of prognostic significance in neuroblastoma using a series of matched neuroblastoma tumour and serum DNA. Here, RASSF1 is linked to neuroblastoma.